Merck's 2008: The Year That Wasn't Trading Markets (press release), CA - In June 2007, FDA rejected Acomplia citing that the drug's benefits did not outweigh its risks. Acomplia was approved in the EU (European Union) in 2006. ...

A study found an anti-obesity drug could lead to psychiatric disorders Free press releases (press release), UK - On October 23, the European Medicines Agency said that a study had found those taking Acomplia , an anti-obesity drug, were at double the risk of developing ...

Solvay Ends Research on Experimental Obesity Drug Network Médica, Argentina - The compound belongs to the same family of drugs as Sanofi-Aventiss Acomplia , approved treatment that was withdrawn from the European market last month. ...

UPDATE 1-Solvay ends research on obesity drug Reuters - Acomplia , which led the field, had already been withdrawn from the European market last month after being linked to mental disorders. ...

Pharma Times (registration) Solvay discontinues research into potential obesity compound Hays Pharma, UK - The company's investigational compound SLV319 was in phase-two development and, according to the company, recent results had "confirmed its clinical ... Tough regulatory climate sees Solvay end trials of SLV319

Competitor Analysis: Cannabinoid CB1 Receptor Antagonists - Out Now MarketWatch - Acomplia (rimonabant) from Sanofi-Aventis is the only representative of this class of CB1 antagonists so far approved. While the FDA rejected approval due ...

That Happened! Sanofi Ends All Human Trials of Acomplia Obesity Drug (Update1) Bloomberg - 5 (Bloomberg) -- Sanofi-Aventis SA, France's largest drugmaker, is halting all human trials of the Acomplia obesity medicine after health authorities in a ... UPDATE 1-Sanofi scraps all trials of Acomplia Diet Drug Acomplia (Rimonabant) Reaches End of Road RIP, Acomplia -

Network Médica Less Is More For Sanofi Forbes, NY - It has been under pressure from a weak dollar, generic competition against its blockbuster sleeping pill and the withdrawal of its Acomplia obesity drug ... 4th UPDATE: Sanofi-Aventis 3Q Pfts Rise 1.9%, Upgrades Guidance Sanofi Increases Forecast as Profit Beats Estimates (Update2) Sanofi profits up as French firm rides out generic storm -

dBTechno Sanofi's Acomplia Failure Threatens Obesity Drug Development Bloomberg - By Frances Schwartzkopff and Trista Kelley Oct. 24 (Bloomberg) -- The failure of Sanofi-Aventis SA's Acomplia weight-loss pill threatens the development of ... Bad news for anti-obesity drug Acomplia UPDATE 3- Acomplia pulled from EU market in blow to Sanofi Sanofi Weighed Down By Acomplia -

Investigational Obesity Drug Highly Effective in Early Trial MedPage Today, NJ - The previous record was 4.7 kg (10.3 lbs) in a one-year trial with rimonabant (Zimulti, Acomplia ). "Our results suggest that tesofensine 0.5 mg might have ... Tesofensine Produces Double the Weight Loss as Currently Approved ... Results back from trial of diet pill UsingAlzheimers drug as slimming pill doubles weight loss